GLP1R and type 2 diabetes mellitus: Based on the slight, non-significant risk reduction of 5% for 3P-MACE in T2D patients at cardiovascular risk without former event, the preventive value of GLP1-RA is discussed for this group of patients (Kristensen et al., 2019).